BioCentury
ARTICLE | Clinical News

Afluria Quadrivalent: Phase III data

October 3, 2016 7:00 AM UTC

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 2,278 children ages 5-17 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferior immunoge...